Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06487546 · ClinicalTrials.gov registry record · NA

Repletion of Ergothioneine in Patients With Kidney Failure

A NA study of ESRD, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06487546 is a NA study of ESRD that is actively recruiting participants, run by Stanford University. The registered enrollment target is 100 participants, below the 133-participant average among 13 other ESRD trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06487546, a NA study of ESRD, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Ergothioneine

Study Locations (1)

California

  • Veterans Affairs Palo Alto - Palo Alto

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-01
Est. Completion 2029-12-01
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT06487546

The ClinicalTrials.gov registry entry for NCT06487546 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 13 other ESRD trials with a reported enrollment target (25% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which Ergothioneine is the first listed.

NCT06487546 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06487546 about?

NCT06487546 is a clinical study titled "Repletion of Ergothioneine in Patients With Kidney Failure". Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to le...

What is the current status of trial NCT06487546?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-04-01. Estimated completion is 2029-12-01.

What conditions does trial NCT06487546 study?

This clinical trial studies the following conditions: ESRD.

What interventions are being tested in trial NCT06487546?

The interventions under investigation include: Ergothioneine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06487546?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06487546 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ESRD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.